Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry (Dexcom Global Registry)

Dexcom Continuous Glucose Monitoring System Use in aReal-World, Global Registry

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06483945

Enrollment

5000

Registered

2024-07-03

Start date

2024-02-28

Completion date

2028-06-30

Last updated

2026-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

"To evaluate the use of the Dexcom CGM System when used according to approved commercial labeling during standard clinical use and its impact on intended users in a real-world setting"

Detailed description

"The Dexcom Global Registry is a non-randomized, open-label, multi-center registry with the goal of collecting Dexcom CGM System data in a real world setting.The registry study involves retrospective and/or prospective data collection associated with Dexcom CGM System use."

Interventions

DEVICEDexcom CGM G6/G6 Pro/G7

Dexcom CGM G6/G6 Pro/G7 device

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Meets Dexcom CGM System Indications for Use (IFU) per approved commercial labeling * Has at least one HbA1C (Hemoglobin a1c) measurement within three (3) months prior to the Dexcom CGM System use start date that is at least three (3) months after any prior CGM use * Subject is willing and able to use Dexcom CGM System according to approved product labeling * Subject is willing and able to complete applicable patient reported outcome assessments/ surveys * Subject is willing and able to comply with the protocol * Subject is willing and able to comply with provider requirements for at least two provider encounters per year according to applicable clinical practice guidelines * Subject or the subject's legally authorized representative must provide written informed consent prior to any study-related data collection or be enrolled under an IRB/EC approved waiver of consent

Exclusion criteria

* Is contraindicated for a Dexcom CGM System per approved commercial labeling * In the Investigator's opinion, the subject is not considered to be a suitable candidate

Design outcomes

Primary

Measure	Time frame	Description
Patient Reported Outcomes (PROs)	4 years	Patients will be asked to complete multiple questionnaires over a period of 4 years for data to be analyzed and reported.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 3, 2026